<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01496495</url>
  </required_header>
  <id_info>
    <org_study_id>ARRAY-614-112</org_study_id>
    <nct_id>NCT01496495</nct_id>
  </id_info>
  <brief_title>A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Array Biopharma, now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Array BioPharma</source>
  <brief_summary>
    <textblock>
      This is a Phase 1 study during which patients with low or intermediate-1 risk myelodysplastic&#xD;
      syndromes (MDS) will receive investigational study drug ARRY-614.&#xD;
&#xD;
      This study has 2 parts. In the first part, patients will receive increasing doses of study&#xD;
      drug in order to achieve the highest dose of the study drug possible that will not cause&#xD;
      unacceptable side effects. Approximately 50 patients from the US will be enrolled in Part 1&#xD;
      (Completed).&#xD;
&#xD;
      In the second part of the study, patients will receive the best dose of study drug determined&#xD;
      from the first part of the study and will be followed to see what side effects and&#xD;
      effectiveness the study drug has, if any, in treating the cancer. Approximately 30 patients&#xD;
      from the US will be enrolled in Part 2 (Completed).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2012</start_date>
  <completion_date type="Actual">March 18, 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Establish the maximum tolerated dose (MTD) of study drug.</measure>
    <time_frame>Part 1, 9 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize the safety profile of the study drug in terms of adverse events, clinical laboratory tests and electrocardiograms.</measure>
    <time_frame>Part 1, 9 months; Part 2, 9 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize the pharmacokinetics (PK) of the study drug and a metabolite in terms of plasma concentrations.</measure>
    <time_frame>Part 1, 9 months; Part 2, 9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the efficacy of the study drug in terms of response, time to response, duration of response, overall survival, hematologic improvement and platelet transfusion independence/reduction.</measure>
    <time_frame>Part 1, 9 months; Part 2, 9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>ARRY-614</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARRY-614, p38/Tie2 inhibitor; oral</intervention_name>
    <description>Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule</description>
    <arm_group_label>ARRY-614</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria (Part 1 and Part 2):&#xD;
&#xD;
          -  Diagnosis of MDS by bone marrow biopsy.&#xD;
&#xD;
          -  International Prognostic Scoring System (IPSS) score of low or intermediate-1 risk&#xD;
             MDS.&#xD;
&#xD;
          -  May have received prior therapy for MDS.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2.&#xD;
&#xD;
          -  Adequate liver and renal function.&#xD;
&#xD;
          -  Additional criteria exist.&#xD;
&#xD;
        Key Exclusion Criteria (Part 1 and Part 2):&#xD;
&#xD;
          -  History of bone marrow transplant.&#xD;
&#xD;
          -  Treatment for MDS other than transfusions or a stable dose (â‰¥ 4 weeks) of&#xD;
             hematopoietic growth factors on the day of the first dose of study drug.&#xD;
&#xD;
          -  Concomitant malignancies or previous malignancies with less than a 2-year disease-free&#xD;
             interval at the time of enrollment.&#xD;
&#xD;
          -  Treatment with an investigational medicinal product that is not expected to be cleared&#xD;
             by the first dose of study drug or that has demonstrated to have prolonged side&#xD;
             effects.&#xD;
&#xD;
          -  Treatment with azacitidine or decitabine within 2 weeks prior to first dose of study&#xD;
             drug.&#xD;
&#xD;
          -  Chronic use (&gt; 2 weeks) of greater than physiologic doses of corticosteroids (dose&#xD;
             equivalent to &gt; 20 mg/day of prednisone) within 4 weeks prior to first dose of study&#xD;
             drug.&#xD;
&#xD;
          -  Treatment with an immunomodulatory agent within 4 weeks prior to the first dose of&#xD;
             study drug.&#xD;
&#xD;
          -  Additional criteria exist.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University, Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>November 28, 2011</study_first_submitted>
  <study_first_submitted_qc>December 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2011</study_first_posted>
  <last_update_submitted>September 4, 2020</last_update_submitted>
  <last_update_submitted_qc>September 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

